ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Files An 8-K Results of Operations and Financial Condition
Item 2.02Results of Operations and Financial Condition.
On February27, 2019, Adaptimmune Therapeutics plc (the Company or Adaptimmune) provided a corporate update and announced its financial results for the fourth quarter ended December31, 2018 and its full-year financial results for the year ended December31, 2018. The press release is furnished as Exhibit99.1 to this report and is incorporated by reference herein.
The information in Item 2.02 of this Form8-K (including the attached Exhibit99.1) shall not be deemed filed for purposes of Section18 of the Securities Exchange Act of 1934, as amended, (the Exchange Act), or incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by the Company by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
Adaptimmune Therapeutics PLC Exhibit
EX-99.1 2 a19-5477_1ex99d1.htm EX-99.1 Exhibit 99.1 Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update – On track for clinical data update from trials in multiple solid tumors at the Q1 2019 earnings update call in May – – Completed initial safety cohorts for ADP-A2M10 (MAGE-A10) in lung and triple tumor studies as well as ADP-A2M4 (MAGE-A4) basket study – – Treating patients in expansion phases of all ADP-A2M10 and ADP-A2M4 studies at target doses of 1 billion cells (with doses up to 10 billion cells) – – Completed Cohort 1 for safety in ADP-A2AFP (AFP) study and treating patients in safety Cohort 2 at target doses of 1 billion cells – – Significant progress in cell and vector manufacturing internally as well as with external partners- – Guidance confirmed: funded through to late 2020 – – Conference call to be held today at 8:00 a.m. EDT (1:00 p.m. GMT) – PHILADELPHIA,…
To view the full exhibit click
About ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP)
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase their affinity to cancer-specific peptides, including its lead target peptides, NY-ESO-1 and MAGE-A10, in order to target and then destroy cancer cells in patients. The Company’s TCR therapeutic candidates are able to target intracellular, as well as extracellular cancer antigens. The TCRs consist of approximately two associated protein chains: the alpha and beta chains. Each of the chains has approximately two regions: a variable region and a constant region.